Array Biopharma, Inc. (NASDAQ: ARRY) reported Q2 EPS of ($0.06), $0.06 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $23.2 million versus the consensus estimate of $21.76 million.

For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.

Earnings